O1 Communique J (ONE.TO) 0.21 $ONE.TO
01 Communique Announces its Shares will Commence Trading on TSX Venture Exchange at the Opening on July 31, 2014
CNW Group - Wed Jul 30, 3:10PM CDT
01 Communique (TSX-V:ONE), announces that it has met the conditional requirements and received approval for its shares to be listed on the TSX Venture Exchange. Effective at the opening Thursday, July 31, 2014, the shares of 01 Communique will commence trading on the TSX Venture Exchange under the same symbol, "ONE".
01 Communique Announces Conditional Approval from TSX Venture Exchange for Listing of its Common Shares.
CNW Group - Wed Jul 16, 3:10PM CDT
01 Communique (TSX:ONE) announced that it has received conditional approval from the TSX Venture Exchange ("TSX-V"
for the listing of its Common Shares. It is anticipated that the first day of trading on the TSX-V will be on or about July 31, 2014 and the last day of trading on the Toronto Stock Exchange ("TSX" will be the day before trading commences on the TSX-V. The trading symbol for the Company will remain the same, which is ONE.
01 Communique Reports Results for Second Quarter Fiscal 2014 and Provides an Update on its Patent Litigation
CNW Group - Mon Jun 09, 3:39PM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its second quarter 2014 which ended April 30, 2014. The loss for the second quarter 2014 was $369,632 compared to a loss of $1,169,030 for the same period in 2013, a decrease of $799,398. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the second quarter 2014 was $324,559 (2013 - $1,066,559) a decrease of $674,625. The Company completed the quarter with $2,101,469 of cash and cash equivalents.
IIROC Trade Resumption - ONE
CNW Group - Mon Jun 09, 11:41AM CDT
Trading resumes in:
01 Communique Provides an Update on its lawsuit against LogMeIn Inc.
CNW Group - Mon Jun 09, 11:33AM CDT
01 Communique (TSX:ONE) announced that the United States Court of Appeals for the Federal Circuit has issued its Order in the Company's appeal of its patent lawsuit against LogMeIn Inc. ("LogMeIn" affirming the district court's finding that LogMeIn did not infringe 01 Communique's patent while also affirming the district court's finding that the patent is valid.
IIROC Trading Halt - ONE
CNW Group - Mon Jun 09, 10:15AM CDT
The following issues have been halted by IIROC:
Xenical (Obesity) - Forecast and Market Analysis to 2022
M2 - Tue Mar 25, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t8wthq/xenical_obesity) has announced the addition of the "Xenical (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Xenical is on patent until 2018 in the US and belongs to a class of drugs known as lipase inhibitors which act on the lipase enzyme to inhibit the absorption of fat in the diet. Dietary fat that is not broken down cannot be absorbed and is eliminated, resulting in a caloric deficit for a positive effect on weight control. Xenical is the only anti-obesity drug approved by the FDA for long-term usage (up to one year) for adults and children age 12 and older. Scope - Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Xenical including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Xenical for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada Key Topics Covered: List of Tables List of Figures Introduction Disease Overview Disease Management Competitive Assessment Xenical (orlistat) Appendix For more information visit http://www.researchandmarkets.com/research/t8...al_obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
01 Communique Announces TSX Listing Review and Provides an Operational Update
CNW Group - Wed Mar 19, 7:30AM CDT
01 Communique (TSX:ONE) announced that the Toronto Stock Exchange ("TSX" has informed the Company that the TSX is reviewing the Common Shares of the Company with respect to meeting the continued listing requirements. Specifically the TSX is reviewing the Company, under Section 710 (b) of the TSX Company Manual, with respect to having total assets of $3.0 million or annual revenue of $3.0 million in the most recent year. At the end of its last reporting period as at January 31, 2014 the Company had $2,893,000 of assets. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process.
TSX Delisting Review - 01 Communique Laboratory Inc. (Symbol: ONE)
CNW Group - Wed Mar 19, 7:30AM CDT
DELISTING REVIEW 01 Communique Laboratory Inc. (the "Company" - TSX is reviewing the common shares (Symbol: ONE) of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process.
01 Communique Reports Results for First Quarter Fiscal 2014
CNW Group - Thu Mar 13, 7:00AM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its first quarter 2014 which ended January 31, 2014. The loss for the first quarter 2014 was $399,367 compared to a loss of $1,060,478 for the same period in 2013, a decrease of $661,111. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the first quarter 2014 was $350,066 (2013 - $875,548). The Company completed the quarter with $2,573,595 of cash and cash equivalents.
Boston Heart Enables Healthcare Providers to Better Identify Near-Term Risk of Heart Attack or Stroke with Launch of an Important Inflammation Marker, Myeloperoxidase (MPO)
PR Newswire - Thu Mar 06, 6:00AM CST
Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.
01 Communique Provides an Update on its Patent Litigation with Citrix Systems Inc.
CNW Group - Tue Feb 25, 9:04AM CST
A Court Order was issued today granting 01 Communique's motion to lift the stay and proceed to trial in its patent lawsuit against Citrix Systems Inc. The action is being returned to the Court's active docket. The Court has scheduled a status conference with the parties for February 28, 2014 to discuss the parties' joint proposed schedule which called for discovery to be completed followed by a pretrial conference to be held on October 17, 2014. At the pretrial conference the trial date will be set.
IIROC Trading Halt - ONE (all issues)
CNW Group - Tue Feb 25, 8:28AM CST
The following issues have been halted by IIROC:
01 Communique Provides an Update on its Patent Litigation against Citrix Systems Inc.
CNW Group - Thu Jan 30, 7:17AM CST
On Wednesday January 29, 2014 a hearing was held on 01 Communique's motion to lift the stay and proceed to trial in its patent lawsuit against Citrix Systems Inc. At the conclusion of the hearing the parties counsel were directed to meet, confer, and prepare a joint proposed schedule addressing the updates and additional discovery that will need to be conducted should the Court decide to lift the stay.
01 Communique Reports Results for Fourth Quarter Fiscal 2013
CNW Group - Wed Dec 18, 3:10PM CST
01 Communique Laboratory Inc. (TSX: ONE) today announced results for its fourth quarter 2013 which ended October 31, 2013. The loss for the fourth quarter 2013 was $357,631 compared to $505,399 in 2012 a decrease of $147,768. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the fourth quarter 2013 was $271,899 compared to $295,991 in 2012. The Company completed the year with $3,072,281 of cash and cash equivalents.
01 Communique Reports Results for Third Quarter Fiscal 2013
CNW Group - Thu Sep 05, 6:30AM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its third quarter 2013 which ended July 31, 2013. The loss for the third quarter 2013 was $584,941 compared to $697,693 in 2012 a decrease of $112,852. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the third quarter 2013 was $235,187 compared to $271,456 in 2012. The Company completed the quarter with $3,566,150 of cash and cash equivalents.
01 Communique Files an Appeal and Provides an Update in its Patent Litigation against LogMeIn
CNW Group - Wed Jun 26, 3:30PM CDT
01 Communique (TSX:ONE) today received the Court Order and Opinion in respect of the post-trial motions in its patent litigation against LogMeIn Inc. ("LogMeIn" . As previously announced, the jury rendered its verdict concluding that LogMeIn does not infringe 01 Communique's patent (U.S. Patent No. 6,928,479). The jury also concluded that 01 Communique's patent is valid.
01 Communique Reports Results for Second Quarter Fiscal 2013
CNW Group - Wed Jun 05, 4:00PM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its second quarter 2013 which ended April 30, 2013. The loss for the second quarter 2013 was $1,169,030 compared to $615,312 in 2012 an increase of $553,718 due primarily to the costs incurred for the LogMeIn Inc. ("LogMeIn" patent lawsuit of $688,000. Excluding non-cash expenses for stock-based compensation and depreciation, and the costs of the LogMeIn lawsuit the loss for the second quarter 2013 becomes $378,701 compared to $395,040 in 2012. The Company completed the quarter with $3,803,212 of cash and cash equivalents.
01 Communique Provides an Update on its Patent Litigation
CNW Group - Thu Apr 04, 7:46AM CDT
01 Communique Laboratory Inc. (TSX:ONE) today provided an update in respect of its patent litigation. On April 2, 2013 the Court entered judgment on the March 26, 2013 jury verdict finding 01's patent number 6928479 (the "479 Patent" valid but not infringed by LogMeIn.
01 Communique Announces its Shares will Commence Trading on TSX Venture Exchange at the Opening on July 31, 2014
CNW Group - Wed Jul 30, 3:10PM CDT
01 Communique (TSX-V:ONE), announces that it has met the conditional requirements and received approval for its shares to be listed on the TSX Venture Exchange. Effective at the opening Thursday, July 31, 2014, the shares of 01 Communique will commence trading on the TSX Venture Exchange under the same symbol, "ONE".
01 Communique Announces Conditional Approval from TSX Venture Exchange for Listing of its Common Shares.
CNW Group - Wed Jul 16, 3:10PM CDT
01 Communique (TSX:ONE) announced that it has received conditional approval from the TSX Venture Exchange ("TSX-V"
for the listing of its Common Shares. It is anticipated that the first day of trading on the TSX-V will be on or about July 31, 2014 and the last day of trading on the Toronto Stock Exchange ("TSX" will be the day before trading commences on the TSX-V. The trading symbol for the Company will remain the same, which is ONE. 01 Communique Reports Results for Second Quarter Fiscal 2014 and Provides an Update on its Patent Litigation
CNW Group - Mon Jun 09, 3:39PM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its second quarter 2014 which ended April 30, 2014. The loss for the second quarter 2014 was $369,632 compared to a loss of $1,169,030 for the same period in 2013, a decrease of $799,398. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the second quarter 2014 was $324,559 (2013 - $1,066,559) a decrease of $674,625. The Company completed the quarter with $2,101,469 of cash and cash equivalents.
IIROC Trade Resumption - ONE
CNW Group - Mon Jun 09, 11:41AM CDT
Trading resumes in:
01 Communique Provides an Update on its lawsuit against LogMeIn Inc.
CNW Group - Mon Jun 09, 11:33AM CDT
01 Communique (TSX:ONE) announced that the United States Court of Appeals for the Federal Circuit has issued its Order in the Company's appeal of its patent lawsuit against LogMeIn Inc. ("LogMeIn"
affirming the district court's finding that LogMeIn did not infringe 01 Communique's patent while also affirming the district court's finding that the patent is valid. IIROC Trading Halt - ONE
CNW Group - Mon Jun 09, 10:15AM CDT
The following issues have been halted by IIROC:
Xenical (Obesity) - Forecast and Market Analysis to 2022
M2 - Tue Mar 25, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t8wthq/xenical_obesity) has announced the addition of the "Xenical (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Xenical is on patent until 2018 in the US and belongs to a class of drugs known as lipase inhibitors which act on the lipase enzyme to inhibit the absorption of fat in the diet. Dietary fat that is not broken down cannot be absorbed and is eliminated, resulting in a caloric deficit for a positive effect on weight control. Xenical is the only anti-obesity drug approved by the FDA for long-term usage (up to one year) for adults and children age 12 and older. Scope - Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Xenical including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Xenical for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada Key Topics Covered: List of Tables List of Figures Introduction Disease Overview Disease Management Competitive Assessment Xenical (orlistat) Appendix For more information visit http://www.researchandmarkets.com/research/t8...al_obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
01 Communique Announces TSX Listing Review and Provides an Operational Update
CNW Group - Wed Mar 19, 7:30AM CDT
01 Communique (TSX:ONE) announced that the Toronto Stock Exchange ("TSX"
has informed the Company that the TSX is reviewing the Common Shares of the Company with respect to meeting the continued listing requirements. Specifically the TSX is reviewing the Company, under Section 710 (b) of the TSX Company Manual, with respect to having total assets of $3.0 million or annual revenue of $3.0 million in the most recent year. At the end of its last reporting period as at January 31, 2014 the Company had $2,893,000 of assets. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process. TSX Delisting Review - 01 Communique Laboratory Inc. (Symbol: ONE)
CNW Group - Wed Mar 19, 7:30AM CDT
DELISTING REVIEW 01 Communique Laboratory Inc. (the "Company"
- TSX is reviewing the common shares (Symbol: ONE) of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process. 01 Communique Reports Results for First Quarter Fiscal 2014
CNW Group - Thu Mar 13, 7:00AM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its first quarter 2014 which ended January 31, 2014. The loss for the first quarter 2014 was $399,367 compared to a loss of $1,060,478 for the same period in 2013, a decrease of $661,111. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the first quarter 2014 was $350,066 (2013 - $875,548). The Company completed the quarter with $2,573,595 of cash and cash equivalents.
Boston Heart Enables Healthcare Providers to Better Identify Near-Term Risk of Heart Attack or Stroke with Launch of an Important Inflammation Marker, Myeloperoxidase (MPO)
PR Newswire - Thu Mar 06, 6:00AM CST
Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.
01 Communique Provides an Update on its Patent Litigation with Citrix Systems Inc.
CNW Group - Tue Feb 25, 9:04AM CST
A Court Order was issued today granting 01 Communique's motion to lift the stay and proceed to trial in its patent lawsuit against Citrix Systems Inc. The action is being returned to the Court's active docket. The Court has scheduled a status conference with the parties for February 28, 2014 to discuss the parties' joint proposed schedule which called for discovery to be completed followed by a pretrial conference to be held on October 17, 2014. At the pretrial conference the trial date will be set.
IIROC Trading Halt - ONE (all issues)
CNW Group - Tue Feb 25, 8:28AM CST
The following issues have been halted by IIROC:
01 Communique Provides an Update on its Patent Litigation against Citrix Systems Inc.
CNW Group - Thu Jan 30, 7:17AM CST
On Wednesday January 29, 2014 a hearing was held on 01 Communique's motion to lift the stay and proceed to trial in its patent lawsuit against Citrix Systems Inc. At the conclusion of the hearing the parties counsel were directed to meet, confer, and prepare a joint proposed schedule addressing the updates and additional discovery that will need to be conducted should the Court decide to lift the stay.
01 Communique Reports Results for Fourth Quarter Fiscal 2013
CNW Group - Wed Dec 18, 3:10PM CST
01 Communique Laboratory Inc. (TSX: ONE) today announced results for its fourth quarter 2013 which ended October 31, 2013. The loss for the fourth quarter 2013 was $357,631 compared to $505,399 in 2012 a decrease of $147,768. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the fourth quarter 2013 was $271,899 compared to $295,991 in 2012. The Company completed the year with $3,072,281 of cash and cash equivalents.
01 Communique Reports Results for Third Quarter Fiscal 2013
CNW Group - Thu Sep 05, 6:30AM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its third quarter 2013 which ended July 31, 2013. The loss for the third quarter 2013 was $584,941 compared to $697,693 in 2012 a decrease of $112,852. Excluding non-cash expenses for stock-based compensation and depreciation the adjusted loss for the third quarter 2013 was $235,187 compared to $271,456 in 2012. The Company completed the quarter with $3,566,150 of cash and cash equivalents.
01 Communique Files an Appeal and Provides an Update in its Patent Litigation against LogMeIn
CNW Group - Wed Jun 26, 3:30PM CDT
01 Communique (TSX:ONE) today received the Court Order and Opinion in respect of the post-trial motions in its patent litigation against LogMeIn Inc. ("LogMeIn"
. As previously announced, the jury rendered its verdict concluding that LogMeIn does not infringe 01 Communique's patent (U.S. Patent No. 6,928,479). The jury also concluded that 01 Communique's patent is valid. 01 Communique Reports Results for Second Quarter Fiscal 2013
CNW Group - Wed Jun 05, 4:00PM CDT
01 Communique Laboratory Inc. (ONE:TSX) today announced results for its second quarter 2013 which ended April 30, 2013. The loss for the second quarter 2013 was $1,169,030 compared to $615,312 in 2012 an increase of $553,718 due primarily to the costs incurred for the LogMeIn Inc. ("LogMeIn"
patent lawsuit of $688,000. Excluding non-cash expenses for stock-based compensation and depreciation, and the costs of the LogMeIn lawsuit the loss for the second quarter 2013 becomes $378,701 compared to $395,040 in 2012. The Company completed the quarter with $3,803,212 of cash and cash equivalents. 01 Communique Provides an Update on its Patent Litigation
CNW Group - Thu Apr 04, 7:46AM CDT
01 Communique Laboratory Inc. (TSX:ONE) today provided an update in respect of its patent litigation. On April 2, 2013 the Court entered judgment on the March 26, 2013 jury verdict finding 01's patent number 6928479 (the "479 Patent"
valid but not infringed by LogMeIn. 
